Immune reconstitution following cellular therapy

IBTS Research Day 2023

Hayley Foy-Stones

Medical Scientist SJH / PhD Student TCD

Cryobiology Laboratory Stem Cell Facility



National Blood Centre St James' Street Dublin 8 Ireland Tel: ++353 1 4162707 hfoystones@stjames.ie cryobiology@stjames.ie



Trinity College Dublin Coláiste na Tríonóide, Baile Átha Cliath



Allogeneic Stem Cell Transplantation

The Stem Cell Transplant (SCT) Service in St James's Hospital was founded in 1984.

Currently the third-largest SCT unit in the UK and Ireland.





An tÚdarás Rialála Táirgí Sláinte Health Products Regulatory Authority

- HPRA TE Licence (TE001)
- JACIE accreditation
- EBMT affiliation

ST JAMES



European Society for Blood and Marrow






<u>Trinity College</u> Dublin Coláiste na Tríonóide. Baile Átha Cliath

Study Design

ST JAMES'S



物义 Irish Blood **Transfusion Service** Seirbhís Fuilaistriúcháin na hÉireann

Trinity College Dublin

Study Group

Characteristic	Value
Number of patients	n=20
Sex	
Male (XY)	13 (65%)
Female (XX)	7 (35%)
Age at transplant	
median (range)	60 (47-71)
Diagnosis	
AML	13 (65%)
MDS	3 (15%)
Myelofibrosis	3 (15%)
CMML	1 (5%)

ST JAMES'S



Trinity College Dublin Coláiste na Tríonóide, Baile Átha Cliath

Study Group

Patients	n=20	
Clinical outcome at 12 months	n	%
Vital status: alive	19	95
Non-relapse mortality (NRM)	0	0
Relapse	3	15
aGvHD	12	60
cGvHD	4	20
Viral reactivation (CMV n=1, EBV n=5, ADV n=5)	11	55
Complications (including, relapse, non relapse mortality, aGvHD, cGvHD and viral reactivation)	18	90





Trinity College Dublin Coláiste na Tríonóide, Baile Átha Cliath The University of Dublin

Fluorochrome	Panel 1	Panel 2	Panel 3	Panel 4
FITC	unstained	CD127	CD14	CD27
PE	unstained	Va7.2TCR	CD56	CCR7
PerCP	unstained	CD3	CD3	CD3
APC	unstained	Vδ3 TCR	CD19	CD45RA
PE/Cy7	unstained	CD4	Va24Ja18 TCR	CD4
APC/Cy7	unstained	CD25	Vδ1 TCR	CD8
Pacific Blue	unstained	CD161	CD16	Vδ2 TCR
eFluor506	unstained	Dead cell stain	Dead cell stain	Dead cell stain





Irish Blood

Trinity College Dublin Coláiste na Tríonóide, Baile Átha Cliath

Cell subsets	Surface expression
Helper T cells	CD3+ CD4+
Cytotoxic T cells	CD3+ CD8+
Regulatory T cells	CD3+ CD4+ CD25+ CD127 ^{lo}
Unconventional T cells	CD3 ⁺ CD4 ⁻ CD8 ⁻ or CD3 ⁺ CD4 ⁺ CD8 ⁺
Natural killer cells	CD3 ⁻ CD56 ⁺ CD16 ^{+/-} (3 subsets depending on CD16 and CD56 expression)
B cells	CD3 ⁻ CD19 ⁺
Monocytes	CD14 ⁺ CD16 ^{+/-} (3 subsets depending on CD16 expression levels)
iNKT cells	CD3+ Va24Ja18 TCR+
MAIT cells	CD3 ⁺ CD161 ⁺ Vα7.2 ⁺
Vδ1 T cells	CD3 ⁺ Vδ1 TCR ⁺
Vδ2 T cells	CD3 ⁺ Vδ2 TCR ⁺
Vδ3 T cells	CD3 ⁺ Vδ3TCR ⁺





Trinity College Dublin Coláiste na Tríonóide, Baile Átha Cliath

Differentiation status of T cell subsets	Surface expression
Naïve T cells	CD3+ CD45RA+ CCR7+ CD4/CD8
Central memory T cells	CD3 ⁺ CD45RA ⁻ CCR7 ⁺ CD4/CD8
Effector memory T cells	CD3 ⁺ CD45RA ⁻ CCR7 ⁻ CD4/CD8
Terminally differentiated T cells	CD3 ⁺ CD45RA ⁺ CCR7 ⁻ CD4/CD8
Naïve Vδ2 T cells	CD3 ⁺ Vδ2 ⁺ CD45RA ⁺ CCR7 ⁺
Central Vδ2 memory T cells	CD3 ⁺ Vδ2 ⁺ CD45RA ⁻ CCR7 ⁺
Effector Vo2 memory T cells	CD3 ⁺ Vδ2 ⁺ CD45RA ⁻ CCR7 ⁻
Terminally differentiated Vδ2 T cells	CD3 ⁺ Vδ2 ⁺ CD45RA ⁺ CCR7 ⁻





Irish Blood

Transfusion Service

Seirbhís Fuilaistriúcháin na hÉireann

ASSOCIATION OF CD56⁺ T CELLS WITH THE ABSENCE OF **CHRONIC GRAFT VERSUS HOST DISEASE IN PATIENTS** UNDERGOING REDUCED-INTENSITY CONDITIONING ALLOGENEIC **STEM CELL TRANSPLANTATION**



H Foy-Stones¹, C Armstrong², N Orfali ², DG Doherty³, AM McElligott³, T Hervig⁴, CL Bacon², E Conneally², C Flynn², P Hayden², PV Browne², E Vandenberghe², R Henderson², M Ní Chonghaile², M McElheron³, N Gardiner¹






HAEMATOLOGY ASSOCIATION OF IRELAND

Presented at:

Cryobiology Laboratory Stem Cell Facility, St. James's Hospital, Dublin, Ireland. ² National Adult Stem Cell Transplant and Adult CAR-T cell Programme, Departmer of Haematology, St. James's Hospital, Dublin, Ireland. ³ Trinity Translational Medicine Institute, Trinity College, Dublin. ⁴ Irish Blood Transfusion Service, Dublin.

Introduction

Despite the efficacy of reduced-intensity conditioning allogeneic stem cell transplantation (RIC allo-SCT) in treating blood cancer, a significant number of patients develop graft versus host disease (GvHD). GvHD occurs when donor T-cells recognise the recipient as foreign and mount an immune response that subsequently causes the destruction of host tissues. Chronic GvHD in particular, results in substantial morbidity and a reduction in the quality of life. We report preliminary results on post-transplant immune monitoring of innate lymphocytes, including CD56* T-cells, gamma delta (γδ) T-cells and NK cells, in patients post-RIC allo-SCT for myeloid malignancy at St James's Hospital.



GvHD manifested in 70% of cases (n=14). Within this group, 13 patients experienced acute GvHD (aGvHD) categorised as grade I (n=4), grade II (n=8) and grade III (n=1). Chronic GvHD (cGvHD) developed in 4 patients, and three of these patients had both aGvHD and cGvHD. The average time to onset of aGvHD was 61±34 days, whereas cGvHD was 299±141 days.

- · At day 28 post-transplant, the mean absolute number of CD56⁺CD3⁺PBMC/ μ L was 3.96 ± 4.18. We observed significantly lower numbers of CD56⁺ T cells in patients who subsequently developed cGvHD compared to those who did not (mean 1.38 ±1.19 vs. 2.65 ±2.66, p=0.039, figure 1a).
- · At day 100 post-transplant, the mean absolute number of CD56+CD3+PBMC/uL was 2.67 ±2.41. Again, a lower mean was observed in patients who subsequently developed cGvHD compared to those who did not (mean 0.87 \pm 0.57 vs. 3.12 ± 2.49, p=0.039, figure 1b).
- At days 28, 60 and 100 post-transplant, we found no associations between CD56+ T-cells and steroid treatment, the incidence of relapse, recipient age, sex or donor age (p>0.05).
- In addition, at days 28, 60 and 100 we found no association between cGvHD and CD4⁺ T cells. CD8⁺ T cells. NK cells. invariant NKT cells and subsets of γδ T cells (p>0.05).




Figure 1: Absolute numbers of CD3⁺CD56⁺ PBMC/µL in patients with Chronic GvHD and patients with no Chronic GvHD at day 28 post RIC allo-SCT (A) and day 100 post RIC allo-SCT (B)




Figure 2: Flow cytometry plots demonstrating CD3⁺CD56⁺ T cells in a patient with Chronic GvHD (A) versus a patient with no Chronic GvHD (B).



Conclusion

Slower CD56* T-cell recovery in the early post-transplant period associates with a higher incidence of subsequent cGvHD. CD56* T cells are a subset of cytotoxic T cells, thought to develop from CD56 negative T cells upon activation, that display both natural and T cell receptor-mediated cytotoxic activity and enhance cytokine secretion. Additional patient testing and functionality studies are warranted to investigate the predictive value and the mechanism by which CD56⁺ T-cells may play a protective role against cGvHD post-RIC allo-SCT without compromising graft versus leukaemia effects.



Trinity College Dublin

HAI Conference 2023

hfoystones@stjames.ie or foystonh@tcd.ie

Presented at:



ASSOCIATION OF CD56⁺ T CELLS WITH THE ABSENCE OF ST. JAMES'S HOSPITAL **CHRONIC GRAFT VERSUS HOST DISEASE IN PATIENTS** CTRG UNDERGOING REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION

Irish Blood Transfusion Service

H Foy-Stones¹, C Armstrong², N Orfali ², DG Doherty³, AM McElligott³, T Hervig⁴, CL Bacon², E Conneally², C Flynn², P Hayden², PV Browne², E Vandenberghe², R Henderson², M Ní Chonghaile², M McElheron³, N Gardiner¹

Cryobiology Laboratory Stem Cell Facility, St. James's Hospital, Dublin, Ireland. ² National Adult Stem Cell Transplant and Adult CAR-T cell Programme, Departmen of Haematology, St. James's Hospital, Dublin, Ireland. ³ Trinity Translational Medicine Institute, Trinity College, Dublin. ⁴ Irish Blood Transfusion Service, Dublin.

Results GvHD manifested in 70% of cases (n=14).

13 patients experienced acute • GvHD (aGvHD): grade I (n=4) grade II (n=8) grade III (n=1).

- Chronic GvHD (cGvHD) • developed in 4 patients
- 3 had both aGvHD and cGvHD.
- The average time to onset of • aGvHD was 61±34 days
- The average time to onset of • cGvHD was 299±141 days.




Trinity College Dublin



ASSOCIATION OF CD56⁺ T CELLS WITH THE ABSENCE OF **CHRONIC GRAFT VERSUS HOST DISEASE IN PATIENTS** ST. JAMES'S H O S P I T A L UNDERGOING REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION

H Foy-Stones¹, C Armstrong², N Orfali ², DG Doherty³, AM McElligott³, T Hervig⁴, Transfusion Service CL Bacon², E Conneally², C Flynn², P Hayden², PV Browne², E Vandenberghe², R Henderson², M Ní Chonghaile², M McElheron³, N Gardiner¹

Cryobiology Laboratory Stem Cell Facility, St. James's Hospital, Dublin, Ireland. 2 National Adult Stem Cell Transplant and Adult CAR-T cell Programme, Departmen of Haematology, St. James's Hospital, Dublin, Ireland. 3 Trinity Translational Medicine Institute, Trinity College, Dublin. 4 Irish Blood Transfusion Service, Dublin



Irish Blood

Results

At day 28 post-transplant, the mean absolute number of CD56⁺CD3⁺PBMC/ μ L was 3.96 ± 4.18.

inity College Dubli

We observed significantly lower numbers of CD56⁺T cells in patients who subsequently developed cGvHD compared to those who did not (mean 1.38 ±1.19 vs. 2.65 ±2.66, p=0.039).

Figure: Absolute numbers of CD3⁺CD56⁺ PBMC/ μ L in patients with Chronic GvHD and patients with no Chronic GvHD at day 28 post RIC allo-SCT.





Trinity College Dublin

IRELAND

HAEMATOLOGY ASSOCIATION OF



Transfusion Service

ASSOCIATION OF CD56⁺ T CELLS WITH THE ABSENCE OF CHRONIC GRAFT VERSUS HOST DISEASE IN PATIENTS UNDERGOING REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION H Fov-Stones¹, C Armstrong², N Orfali ², DG Doherty³, AM McElligott³, T Hervig⁴,


H Foy-Stones¹, C Armstrong², N Orfali ², DG Doherty³, AM McElligott³, T Hervig⁴, CL Bacon², E Conneally², C Flynn², P Hayden², PV Browne², E Vandenberghe², R Henderson², M Ní Chonghaile², M McElheron³, N Gardiner¹



HAEMATOLOGY ASSOCIATION OF IRELAND

Cryobiology Laboratory Stem Cell Facility, St. James's Hospital, Dublin, Ireland. * National Adult Stem Cell Transplant and Adult CAR-T cell Programme, Department of Haematology, St. James's Hospital, Dublin, Ireland. * Trinity Translational Medicine Institute, Trinity College, Dublin. * Irish Blood Transfusion Service, Dublin.






CD3

Figure: Flow cytometry plots demonstrating CD3⁺CD56⁺ T cells in a patient with Chronic GvHD (A) versus a patient with no Chronic GvHD (B).









At day 100 post-transplant, the mean absolute number of CD56+CD3+PBMC/ μ L was 2.67 ±2.41.

Again, a lower mean was observed in patients who subsequently developed cGvHD compared to those who did not (mean 0.87 \pm 0.57 vs. 3.12 \pm 2.49, p=0.039.

Figure: Absolute numbers of CD3⁺CD56⁺ PBMC/ μ L in patients with Chronic GvHD and patients with no Chronic GvHD at day 100 post RIC allo-SCT.





ST JAMES'S



Presented at:

ASSOCIATION OF CD56⁺ T CELLS WITH THE ABSENCE OF CHRONIC GRAFT VERSUS HOST DISEASE IN PATIENTS UNDERGOING REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION

Irish Blood Transfusion Service Seithis futaistrüchün na hÉireann H Foy-Stones¹, C Armstrong², N Orfali ², DG Doherty³, AM McElligott³, T Hervig⁴, CL Bacon², E Conneally², C Flynn², P Hayden², PV Browne², E Vandenberghe², R Henderson², M Ní Chonghaile², M McElheron³, N Gardiner¹



Cryobiology Laboratory Stem Cell Facility, St. James's Hospital, Dublin, Ireland. ² National Adult Stem Cell Transplant and Adult CAR-T cell Programme, Department of Haematology, St. James's Hospital, Dublin, Ireland. ³ Trinity Translational Medicine Institute, Trinity College, Dublin. ⁴ Irish Blood Transfusion Service, Dublin.

Results

At days 28, 60 and 100 posttransplant, we found no associations between CD56⁺ Tcells and steroid treatment, the incidence of relapse, recipient age, sex or donor age (p>0.05). In addition, at days 28, 60 and 100 we found no association between cGvHD and CD4⁺ T cells, CD8⁺ T cells, NK cells, invariant NKT cells and subsets of $\gamma\delta$ T cells (p>0.05).



ransfusion Service



Presented at:

ASSOCIATION OF CD56⁺ T CELLS WITH THE ABSENCE OF CHRONIC GRAFT VERSUS HOST DISEASE IN PATIENTS UNDERGOING REDUCED-INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION



H Foy-Stones¹, C Armstrong², N Orfali ², DG Doherty³, AM McElligott³, T Hervig⁴, CL Bacon², E Conneally², C Flynn², P Hayden², PV Browne², E Vandenberghe², R Henderson², M Ní Chonghaile², M McElheron³, N Gardiner¹

Cryobiology Laboratory Stem Cell Facility, St. James's Hospital, Dublin, Ireland. ² National Adult Stem Cell Transplant and Adult CAR-T cell Programme, Departmen of Haematology, St. James's Hospital, Dublin, Ireland. ³ Trinity Translational Medicine Institute, Trinity College, Dublin. ⁴ Irish Blood Transfusion Service, Dublin.


Conclusion

- CD56⁺ T cells are a subset of cytotoxic T cells, thought to develop from CD56 negative T cells upon activation, that display both natural and T cell receptormediated cytotoxic activity and enhance cytokine secretion.
- Slower CD56⁺ T-cell recovery in the early post-transplant period associates with a higher incidence of subsequent cGvHD.
- Additional patient testing and functionality studies are warranted to investigate the predictive value and the mechanism by which CD56⁺ T-cells may play a protective role against cGvHD post-RIC allo-SCT without compromising graft versus leukaemia effects.





Chimeric Antigen Receptor T (CAR-T) Cells




Created using BioRender.com

At present, two different second-generation CAR constructs have been licenced for the treatment of relapsed/refractory high-grade B-cell malignancies at St. James's Hospital, since 2021.





Study Design



Immune monitoring of CAR-T cell therapy recipient





Trinity College Dublin Coláiste na Tríonóide, Baile Átha Cliath

Study Group

Patients	n=10	
Sex	n	%
Male (XY)	7	70
Female (XX)	3	30
CAR-T product	n	%
Kymriah®	8	80
Yescarta®	2	20
Clinical outcome at 6 months	n	%
Complete remission (CR)	6	60
Partial response (PR)	1	10
Persistent disease (PD)	3	30

ST JAMES'S HOSPITAL



ST JAMES'S H O S P I T A L

Fluorochrome	Panel 5
FITC	PD-1
PE	CD19 CAR detection
PerCP	CD3
APC	CTLA-4
PE/Cy7	TIM-3
APC/Cy7	BTLA
Pacific Blue	LAG-3
eFluor506	Dead cell stain

AND Immune panels 1 – 4 as shown for allo-SCT



Trinity College Dublin Coláiste na Tríonóide, Baile Átha Cliath The University of Dublin

甥又



Crvobi

SERIAL MONITORING OF CIRCULATING CD19 CAR-T CELLS IN PATIENTS POST CAR-T CELL THERAPY

H Foy-Stones¹, CL Bacon², C Armstrong², A Kilgallon³, DG Doherty³, AM McElligott³, T Hervig⁴, N Casey¹, N Orfali ², E Vandenberghe², R Henderson², E Higgins², N Gardiner ST JAMES'S


Trinity College Dublin Galiste na Thunida, Balle Àtha Clach The University of Dublin

y Laboratory Stem Cell Facility, St. James's Hospital, Dublin, Ireland. ² National Adult Stem Cell Transplant and Adult CAR-T cell Programme, Department of pgy, St. James's Hospital, Dublin, Ireland. ⁴ Trinity Translational Medicine Institute, Trinity College, Dublin, Ireland. ⁴ Irish Blood Transfusion Service, Dublin.

INTRODUCTION

- Chimeric antigen receptor T cell (CAR-T) therapy has demonstrated success in the treatment of relapsed/refractory high-grade B-cell malignancies.
- Currently, the most utilised target for CAR-T cell therapy is the B-cell surface antigen CD19. However, with reported response rates of up to 50%, we are left with the question of what differentiates responders from non-responders, as various factors play a role in the success of CAR-T.
- Here we report preliminary results on serial monitoring of circulating CD19 CAR-T cells in patients' peripheral blood mononuclear cells (PBMCs) post-CAR-T cell therapy, to assess if CAR-T cell persistence is a useful indicator for patient outcome.

METHODS



RESULTS

Table 1: Characteristics of the study cohort.				
Patients		n=10		
Sex	n	%		
Male (XY)	7	70		
Female (XX)	3	30		
CAR-T product	n	%		
Kymriah®	8	80		
Yescarta®	2	20		
Clinical outcome at 6 months	n	%		
Complete remission (CR)	6	60		
Partial response (PR)	1	10		
Persistent disease (PD)	3	30		

Objective 1: Monitoring CD19 CAR-T cell persistence.





Figure 1: Longitudinal monitoring of CD19 CAR-1 cells in patients' blood postinfusion by flow cytometry (A) and the mean percentages and numbers of T cells that express the CD19 CAR at 1, 3 and 6 months (B).



CD3*CD19CAR* PBMC/ μ L (B) at 1,3 and 6 months post CAR-T in patients with a complete response (CR), partial response (PR) and persistent disease (PD).

Objective 2: Monitoring B cells as a surrogate marker of CD19 CAR-T cell function.




Figure 3: Monitoring of B cells [CD3·CD19·] at 1, 3 and 6 months post CAR-T cell therapy in patients with a complete response (CR), partial response (PR) and persistent disease (PD).

- CAR-T cell persistence decreases over time (figure 1b).
- A higher mean percentage of CD19 CAR-T cells was observed at 1 and 3 months post-infusion in the CR group compared to the PD group (*figure 2a*).
- In contrast, at 6 months, a higher mean percentage of CD19 CAR-T cells was observed in the PD group compared to the CR group (*figure 2a*).
- Higher absolute numbers of CD3⁺CD19CAR⁺ PBMC/µL were observed in the CR group compared to the PD group at 1, 3 and 6 months post CAR-T cell therapy (*figure 2b*).
- At 6 months post-CAR-T, we observed a small CD19 B-cell population in one patient with persistent disease (*figure 3*).

CONCLUSION

 We predict that longitudinal monitoring of CD19 CAR-T cells at further time points will shed light on whether the persistence of CD19 CAR is one of the contributing factors that can differentiate between responders and nonresponders.








Preliminary Presented at: Blood HAEMATOLOGY Cance **Results** ASSOCIATION OF IRELAND CTRG. SERIAL MONITORING OF CIRCULATING CD19 CAR-T CELLS IN ST JAMES'S PATIENTS POST CAR-T CELL THERAPY Trinity College Dublir Irish Blood H Foy-Stones¹, CL Bacon², C Armstrong², A Kilgallon³, DG Doherty³, AM McElligott³, Transfusion Service T Hervig⁴, N Casey¹, N Orfali², E Vandenberghe², R Henderson², E Higgins², N Gardir n<u>y Stem Cell Facility, St. James's H</u>ospital, Dublin, Ireland. ² National Adult Stem Cell Transplant and Adult CAR-T cell Programme, Dep ¹ Cryobio logy Labor

in Ireland ³ Trinity Translational Medicine Institute Trinity College Dub

Results



ST JAMES'S HOSPITAL




Figure: Longitudinal monitoring of CD19 CAR-T cells in patients' blood postinfusion by flow cytometry (A) and the mean percentages and numbers of T cells that express the CD19 CAR at 1, 3 and 6 months (B).

> Trinity College Dublin Coláiste na Tríonóide, Baile Átha Cliath The University of Dublin

Irish Blood

Transfusion Service



Results

lin, Ireland, ³ Trinity Translational Medicine Institute, Trinity College, Dub




Figure: CD19 CAR-T cell percentage at 1, 3 and 6 months post CAR-T cell therapy in patients with a complete response (CR), partial response (PR) and persistent disease (PD).

ST JAMES'S HOSPITAL

- At the 1 and 3 months post-CAR-T cell therapy, the mean CD19 CAR percentage was highest in the CR group.
- At 6 months we observed a higher CD19 CAR percentage in the PD group.

氛


Irish Blood

Transfusion Service

Trinity College Dublin



Results



At the 1, 3 and 6
months post-CAR-T
cell therapy, the mean
CD3⁺CD19CAR⁺
PBMC/μL was highest
in the CR group
compared to the PD
group.

氛


Irish Blood

Transfusion Service

Figure: CD3⁺CD19CAR⁺ PBMC/ μ L (B) at 1, 3 and 6 months post CAR-T cell therapy in patients with a complete response (CR), partial response (PR) and persistent disease (PD).











Irish Blood

Transfusion Service

EXPRESSION OF EXHAUSTION MARKERS ON THE SURFACE OF CAR-T CELLS AND T-CELLS IN THE RECIPIENTS OF CD19 CAR-T CELL THERAPY CTRG.

H Foy-Stones¹, CL Bacon², C Armstrong², A Kilgallon³, DG Doherty³, AM McElligott³, T Hervig⁴, N Casev¹, N Orfali², E Vandenberghe², R Henderson², E Higgins², N Gardiner¹,




Cryobiology Laboratory Stem Cell Facility, St. James's Hospital, Dublin. ² National Adult Stem Cell Transplant and Adult CAR-T cell Programme, Department of Haematology, St. James's Hospital, Dublin. * Trinity Translational Medicine Institute, Trinity College, Dublin. * Irish Blood Transfusion Service, Dublin.

INTRODUCTION

- T-cell exhaustion is a state of functional impairment that occurs due to prolonged exposure to antigenic stimulation.
- · In chronic infections and cancer, these exhausted Tcells can lose their ability to respond to antigens. The dynamics of T-cell exhaustion involves the expression of a number of receptors on T cells and their inhibitory ligands on other cells.
- · We present our preliminary findings of exhaustion markers on circulating T-cells and CD19 CAR-T cells post CAR-T-cell infusion.

OBJECTIVES

· Correlate the exhaustion marker profile of T cells and CD19 CAR-T cells with the clinical outcomes post CAR-T cell therapy.



TIM-3 expression on CD19 CAR-T cells




Figure 1: Percentage of TIM-3 expression on CD3⁺CD19CAR⁺ T-cells at 1, 3 and 6 months post-CAR-T in patients with a complete response (CR), partial response (PR) and persistent disease (PD).

- At 1, 3 and 6 months post-CAR-T cell therapy, the mean percentage of TIM-3⁺CD3⁺CD19CAR⁺ was 67%.
- On CD19 CAR T-cells, we observed a slightly higher mean percentage of TIM-3 in the CR group at 1 month post-infusion, and then in the PD and PR groups at 3 and 6 months post-infusion (figure 1).


CTLA-4 expression on CD19 CAR-T cells

- The mean percentage of CTLA4⁺CD3⁺CD19CAR⁺ was 34%.
- CTLA-4 was seen at higher levels on CD19-CAR-T cells in the PD group at the 1, 3 and 6-month time points.

LAG-3 expression on CD19 CAR-T cells

We observed, that LAG-3 expression levels were the lowest of all exhaustion markers that were monitored during our study. Across all time points, the mean percentage of LAG-3⁺CD3⁺CD19CAR⁺ was 6%.

HAI Conference 2023



RESULTS

Figure 2: Percentage of PD-1 expression on CD3⁺CD19CAR⁺ T-cells at 1, 3 and 6 months post-CAR-T in patients with a complete response (CR), partial response (PR) and persistent disease (PD)

- The mean percentage of PD-1⁺CD3⁺CD19CAR⁺ was 51%.
- At 1-month post-infusion, the expression of PD-1 on CAR-T cells was similar between all groups, (figure 2).
- At 3 and 6 months post-infusion, our PD group expressed slightly higher levels of PD-1 on CD19 CAR Tcells (figure 2).

BTLA expression on CD19 CAR-T cells




Figure 3: Percentage of BTLA expression on CD3+CD19CAR+ T-cells at 1. 3 and 6 months post-CAR-T in patients with a CR. PR and PD.

- The mean percentage of BLTA⁺CD3⁺CD19CAR⁺ was 50%.
- The expression of BTLA on CD19 CAR-T cells was slightly higher in the PD and PR groups at 3 and 6 months postinfusion (figure 3).

Exhaustion marker expression on CD3⁺ T cells

- The mean percentage of exhaustion marker expression on CD3⁺ T cells post CAR-T cell therapy varied between each of the markers: TIM-3 (25.5%), PD-1 (18%), BTLA (12%) CTLA-4 (10%) and LAG-3 (0.11%).
- At 1 month, the CR group had higher percentages of TIM-3 and PD-1 on T cells compared to the PD group.
- At 3 and 6 months, the CR group had higher percentages of TIM-3, whereas the PD group had higher percentages of PD-1 and BTLA.

CONCLUSION

- · We observed high levels of exhaustion markers on the surface of CAR-T cells and T-cells post-infusion. Despite the apparent negative aspects of T-cell exhaustion, our preliminary research has suggested that early expression at 1 month, might be associated with a positive overall outcome.
- · Further research on additional patients at further time points is required to determine if these exhaustion markers are a negative or positive indicator of overall outcome post-CAR-T cell therapy.

Trinity College Dublin


ST JAMES'S HOSPITAL





Exhaustion Markers

T cell exhaustion is a state of functional impairment, that occurs due to prolonged exposure to antigenic stimulation.



The dynamics of T cell exhaustion involve the expression of several receptors on T cells:

 TIM-3 (T-cell immunoglobulin and mucin domain-3) LAG-3 (Lymphocyte activation gene-3)
 PD-1 (Programmed cell death protein 1) BTLA (B and T lymphocyte attenuator)
 CTLA-4 (Cytotoxic T-lymphocyte–associated antigen 4)

T-cell exhaustion also involves: the expression of inhibitory ligands on other cells.






ST JAMES



AND T-CELLS IN THE RECIPIENTS OF CD19 CAR-T CELL THERAPY CTRG. TJAMES'S H Foy-Stones¹, CL Bacon², C Armstrong², A Kilgallon³, DG Doherty³, AM McElligott³, T Hervig⁴, N Casey¹, N Orfali², E Vandenberghe², R Henderson², E Higgins², N Gardiner¹ Cryobiology Laboratory Stem Cell Facility, St. James's Hospital, Dublin, 2 National Adult Stem Cell Transplant and Adult CAR-T cell Programme, Department o Haematology, St. James's Hospital, Dublin, ³ Trinity Translational Medicine Institute, Trinity College, Dublin,⁴ Irish Blood Transfusion Service, Dublin,

Results

Expression of TIM-3 on CD19 CAR-T cells post CAR-T cell therapy



At 1, 3 and 6 months post-CAR-T cell therapy, the mean percentage of

TIM-3⁺CD3⁺CD19CAR⁺ was 67%.

On CD19 CAR T-cells, we observed a slightly higher mean percentage of TIM-3 in the CR group at 1 month postinfusion, and then in the PD and PR groups at 3 and 6 months post-infusion.

Figure: Percentage of TIM-3 expression on CD3+CD19CAR+ T-cells at 1, 3 and 6 months post-CAR-T in patients with a complete response (CR), partial response (PR) and persistent disease (PD).



Irish Blood

<u>Trinity College</u> Dublin

ST JAMES'S



EXPRESSION OF EXHAUSTION MARKERS ON THE SURFACE OF CAR-T CELLS AND T-CELLS IN THE RECIPIENTS OF CD19 CAR-T CELL THERAPY And the second of the s

Results

Expression of PD-1 on CD19 CAR-T cells post CAR-T cell therapy




Figure: Percentage of PD-1 expression on CD3⁺CD19CAR⁺ T-cells at 1, 3 and 6 months post-CAR-T in patients with a complete response (CR), partial response (PR) and persistent disease (PD).

- The mean percentage of PD-1⁺
 CD3⁺CD19CAR⁺ was 51%.
- At 1-month post-infusion, the expression of PD-1 on CAR-T cells was similar between all groups.
- At 3 and 6 months postinfusion, our PD group expressed slightly higher levels of PD-1 on CD19 CAR T-cells.

Coláiste na Trí

Irish Blood

Transfusion Service


ST JAMES'S









Expression of BTLA on CD19 CAR-T cells post CAR-T cell therapy







٠

Irish Blood

Transfusion Service eirbhís Fuilaistriúcháin na hÉireann

Figure: Percentage of BTLA expression on CD3+CD19CAR+ T-cells at 1, 3 and 6 months post-CAR-T in patients with a CR, PR and PD.

- The mean percentage of BLTA⁺CD3⁺CD19CAR⁺ was 50%.
- The expression of BTLA on CD19 CAR-T cells was slightly higher in the PD and PR groups at 3 and 6 months post-infusion.

Trinity College Dublin



EXPRESSION OF EXHAUSTION MARKERS ON THE SURFACE OF CAR-T C	
CTRG. AND T-CELLS IN THE RECIPIENTS OF CD19 CAR-T CELL THERAPY	ST JAMES
H Foy-Stones ¹ , CL Bacon ² , C Armstrong ² , A Kilgallon ³ , DG Doherty ³ , AM McElligott ³ , T Hervig ⁴ , N Casey ¹ , N Orfali ² , E Vandenberghe ² , R Henderson ² , E Higgins ² , N Gardiner ¹ .	Si V Colliste su Trimi De University of
¹ Cryobiology Laboratory Stem Cell Facility, St. James's Hospital, Dublin. ² National Adult Stem Cell Transplant and Adult CAR-T cell Programme,	Departme




- We observed **high levels of exhaustion markers** on the surface of CAR-T cells and T-cells post-infusion. Despite the apparent negative aspects of T-cell exhaustion, our preliminary research has suggested that early expression at 1 month, might be associated with a positive overall outcome.
- Further research on additional patients at further time points is required to determine if these exhaustion markers are a **negative or positive indicator** of overall outcome post-CAR-T cell therapy.





Planned future work: KIR profiling at IBTS



Killer cell immunoglobulin-like receptors (KIR):

Expressed on natural killer (NK) cells

Plan to analyse donor and recipient KIR profiles

Assess the correlation of the KIR profile with the clinical outcomes (GvHD, Relapse)





Acknowledgements – thank you!


PhD supervisors:



Dr Nicola Gardiner



Prof. Tor Hervig



A special thanks to all **patients** for participating in the Trinity/St James's Hospital Blood Cancer Biobank!

SJH staff: Cryobiology laboratory, haematology consultants, CAR-T coordinators, nursing and phlebotomy.

Cellular Therapy Research Grou



Cellular Therapy Research Group (CTRG):



- Prof. Larry Bacon
- Dr Nina Orfali

Dr Christopher Armstrong

Dr Aoife Kilgallon

Dr Joanne Lysaght

Dr Robert Henderson

Dr Diarmaid O Donghaile

Irish Blood

ransfusion Service

Dr Richard Hagan

Dr Allison Waters











Trinity College Dublin Coláiste na Tríonóide, Baile Átha Cliath The University of Dublin

物义

Any Quesions